RGNX
NASDAQ · Biotechnology
Regenxbio Inc
$7.88
-0.46 (-5.52%)
Financial Highlights (FY 2026)
Revenue
85.50M
Net Income
-233,014,819
Gross Margin
59.7%
Profit Margin
-272.5%
Rev Growth
-43.8%
D/E Ratio
0.23
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 59.7% | 59.7% | 65.6% | 65.6% |
| Operating Margin | -280.0% | -252.0% | 22.7% | 23.0% |
| Profit Margin | -272.5% | -258.9% | 16.1% | 20.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 85.50M | 152.21M | 81.92M | 77.44M |
| Gross Profit | 51.06M | 90.90M | 53.74M | 50.80M |
| Operating Income | -239,419,662 | -383,617,047 | 18.58M | 17.83M |
| Net Income | -233,014,819 | -373,354,703 | 13.19M | 16.19M |
| Gross Margin | 59.7% | 59.7% | 65.6% | 65.6% |
| Operating Margin | -280.0% | -252.0% | 22.7% | 23.0% |
| Profit Margin | -272.5% | -258.9% | 16.1% | 20.9% |
| Rev Growth | -43.8% | -43.8% | +8.8% | +5.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 41.26M | 41.26M | 100.32M | 116.10M |
| Total Equity | 179.46M | 179.46M | 233.09M | 229.51M |
| D/E Ratio | 0.23 | 0.23 | 0.43 | 0.51 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -221,859,611 | -375,229,892 | 28.49M | 26.62M |
| Free Cash Flow | — | — | 20.59M | 19.17M |